Executive Summary

Nuo Therapeutics, Inc. (“Nuo” or the “Company”) has released its Annual Report for the fiscal year ended December 31, 2025. This report provides critical insights into the Company’s financial position, risk factors, and operational trajectory. Nuo’s business centers around its flagship product, the Aurix System, targeting the advanced wound care market. Investors should carefully review the contents of this report, as several elements have material implications for share value and the Company’s future.

Key Price-Sensitive Highlights for Shareholders

• Revenue Base Limited to Aurix Product:
  The Company’s current revenues are solely derived from the Aurix product line, including private label arrangements. This concentration heightens the Company’s exposure to product-specific risks and market adoption challenges.
• Going Concern Risk and Capital Needs:
  Nuo faces significant uncertainty regarding its ability to continue as a going concern. Its limited cash resources and reliance on external capital raises (both equity and debt) may lead to substantial dilution for existing shareholders and could materially affect share value, especially if additional capital is raised at low share prices.
• Material Weaknesses in Internal Controls:
  The Company disclosed that its internal control over financial reporting was not effective as of December 31, 2025, due to continuing material weaknesses. Although remediation efforts are underway, these weaknesses pose a risk of financial misstatement and could harm investor confidence.
• Heavy Reliance on Smith+Nephew Distribution Agreement:
  The Company’s distribution agreement with Smith+Nephew is critical to revenue generation. The agreement includes binding notification and negotiation rights, minimum purchase commitments, and other financial obligations that may limit Nuo’s strategic flexibility, including licensing and business combinations.
• Potential for Significant Dilution:
  During 2025, Nuo raised \$791,418 from a private placement, \$113,541 from option exercises, and \$500,000 as prefunding for two secured notes. The Company warns that additional capital raising will likely continue and could be significantly dilutive to current shareholders.
• Stock Trading and Liquidity Risks:
  Nuo’s shares trade on the OTCQB under the symbol “AURX” and are considered “penny stock” under SEC regulations. This designation imposes additional trading restrictions, reduces liquidity, and may discourage broker-dealers from facilitating trades, potentially impairing shareholders’ ability to exit positions.
• Ownership Concentration:
  As of March 15, 2026, executive officers, directors, and three principal shareholders collectively control over 60% of the outstanding shares, giving them significant influence over corporate decisions, which may not align with the interests of minority shareholders.
• No Dividend Policy:
  Nuo has never declared or paid cash dividends and does not intend to do so, instead opting to reinvest any future earnings into the business.
• Legal Proceedings:
  There are currently no material legal proceedings pending against the Company.

Operational and Financial Review

• Cash Flow and Financing:
  For 2025, net cash used in operating activities was \$(2.2) million, with additional cash outflows for investing activities of \$(274,756). Financing activities (primarily from equity raises and prefunding of notes) provided \$1.4 million, but the Company continues to face substantial cash burn and will require further capital raises.
• Off-Balance Sheet Arrangements:
  Nuo has no off-balance sheet arrangements, reducing the risk of hidden liabilities.
• Inflation:
  The Company does not believe inflation has had a material impact on its operations for the reporting period.

Material Weaknesses and Remediation Plan

• Background:
  Nuo ceased ongoing operational activities in 2019 and only restarted commercial operations in 2022. As a result, a material weakness in internal controls persists.
• Remediation Efforts:
  The Company has engaged outside consultants and plans to further strengthen its internal accounting and financial reporting functions as resources allow. However, there is no guarantee that these efforts will be sufficient or timely.
• Risks:
  Failure to remediate these weaknesses could result in financial misstatements, loss of investor confidence, regulatory action, and litigation.

Risks and Uncertainties

• Competitive, Regulatory, and Market Risks:
  The Company faces risks related to competitive products, regulatory changes (especially regarding Medicare and private payor reimbursement), intellectual property challenges, supply chain dependence on single source suppliers, and the ability to attract and retain key personnel.
• Market Volatility:
  The share price is susceptible to wide fluctuations based on business performance, capital raises, management stock sales, and overall market sentiment.
• Cybersecurity and Data Privacy:
  The Company acknowledges cybersecurity and data privacy as material risks, with potential for regulatory, reputational, and financial harm in the event of a breach.

Trading and Shareholder Information

• OTCQB Listing:
  Shares are quoted on the OTCQB tier, which may limit trading liquidity and access to institutional investors.
• Approximately 800 Record Holders:
  As of March 15, 2026.
• Penny Stock Rules:
  Trading is subject to additional disclosures and suitability requirements, which may further limit liquidity.

Conclusion and Outlook

Nuo Therapeutics, Inc. remains highly speculative and is at a critical juncture. The Company’s sole dependence on the Aurix product, persistent internal control weaknesses, ongoing capital needs, and the restrictive terms of its principal distribution agreement present substantial risks. While management is actively seeking to address these issues, the success of remediation efforts and future capital raising is uncertain. Investors should be aware that price-sensitive events—such as new capital raises, changes in reimbursement status, or resolution of internal control weaknesses—could significantly move the share price.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. The information is based on the Company’s 2025 Annual Report and may not reflect the most current developments.